Tag Archives: MET

Business, Finance, Occupation & Industry

ArQule Regains Worldwide Rights to AKT Program

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

ArQule Regains Worldwide Rights to AKT Program

Encouraging Phase 1 data with lead compound, ARQ 092, to be presented at AACR

WOBURN, Mass.–(BUSINESS WIRE)– ArQule, Inc. (NAS: ARQL) today announced it has regained worldwide rights for the development and commercialization of compounds covered under its AKT collaboration with Daiichi Sankyo Co., Ltd., including the lead compound emerging from this collaboration, ARQ 092. Data from an ongoing Phase 1 trial with ARQ 092 will be presented at the AACR (American Association for Cancer Research) Annual Meeting on April 9, 2013.

“Regaining worldwide rights to the AKT program, including the novel oral agent, ARQ 092, adds significant value for ArQule, as it expands our proprietary pipeline in an exciting area of therapeutic development,” said Brian Schwartz, M.D., chief medical officer of ArQule. “AKT, also known as the serine/threonine kinase PKB, is believed to mediate a number of signal transduction processes and represents a potential therapeutic target for several cancers and other diseases. We look forward to the AACR data presentation from the ongoing Phase 1 trial with ARQ 092.”

ARQ 092 is a selective AKT inhibitor that was discovered through technology from the ArQule Kinase Inhibitor Platform (AKIP™) and optimized through a structure-based drug design methodology. The AKT signaling pathway, which plays a role in regulating cell growth, survival, migration and angiogenesis, is frequently dysregulated in cancer.

ArQule is regaining its rights to the AKT program and to ARQ 092 pursuant to Daiichi Sankyo‘s decision to terminate a license and co-commercialization agreement with ArQule dated November 8, 2011.

About ArQule

ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to human cancers. ArQule’s lead product, in Phase 2 and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline consists of ARQ 092, designed to inhibit AKT, ARQ 087, designed to inhibit fibroblast growth factor receptor (FGFR), ARQ 621, designed to inhibit the Eg5 kinesin motor protein, and ARQ 736, designed to inhibit the RAF kinases. ArQule’s current discovery efforts, which are based on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the identification of novel kinase …read more
Source: FULL ARTICLE at DailyFinance

Business, Finance, Occupation & Industry

ArQule Reports Fiscal 2012 Year End and Fourth Quarter Results

Leave a comment

By Business Wirevia The Motley Fool

Filed under:

ArQule Reports Fiscal 2012 Year End and Fourth Quarter Results

Conference call scheduled today at 9:00 a.m. eastern time

WOBURN, Mass.–(BUSINESS WIRE)– ArQule, Inc. (NAS: ARQL) today announced its financial results for the year and for the fourth quarter ended December 31, 2012.

The Company reported a net loss of $10,872,000 or $0.18 per share, for the year ended December 31, 2012, compared with a net loss of $10,762,000, or $0.20 per share, for the year ended December 31, 2011. For the quarter ended December 31, 2012, the Company reported a net loss of $5,296,000 or $0.09 per share, compared with net income of $3,768,000, or $0.07 per share, for the quarter ended December 31, 2011.

At December 31, 2012, the Company had a total of approximately $130,599,000 in cash and marketable securities.

Operational Milestones

Tivantinib (ARQ 197)

  • Presentation of data at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) from a randomized, double-blind, controlled Phase 2 trial of tivantinib in second-line hepatocellular carcinoma (HCC) that met the primary endpoint of time to progression, with pronounced improvements observed in median overall survival and progression free survival in MET-high patients;
  • Dosing of the first patient in the pivotal Phase 3 METIV-HCC trial of tivantinib as a single agent in second-line HCC MET-high patients in January 2013;
  • Agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the design of the METIV-HCC trial;
  • Discontinuation of the Phase 3 MARQUEE trial of tivantinib and erlotinib in non-squamous non-small cell lung cancer (NSCLC), conducted by our partner Daiichi Sankyo Co., Ltd., following an interim analysis, with patients already on treatment and re-consented continuing to receive treatment;
  • Permanent suspension of enrollment in the Phase 3 ATTENTION trial of tivantinib and erlotinib in non-squamous NSCLC in Asia conducted by our partner, Kyowa Hakko Kirin Co., Ltd., with patients already enrolled and re-consented continuing to receive treatment;
  • Announcement of top-line …read more
    Source: FULL ARTICLE at DailyFinance
Linux

Blade 1500 Silver

Leave a comment

By MadeInGermany

CPU/Speed: UltraSPARC-IIIi/1.5Ghz
Ram: 1GB
Motherboard: Sparc
Bus: PCI
Cache:
Controller:
Disk: ATA
Load: 1 user
Kernel: SunOS 5.10 Generic_137111-02
Kernel ELF?: yes
pgms: gcc 2.95.3 compiled

BYTE UNIX Benchmarks (Version 3.11)
System — SunOS aachen95 5.10 Generic_137111-02 sun4u sparc SUNW,Sun-Blade-1500
Start Benchmark Run: Tue Feb 12 18:36:33 MET 2013
10 interactive users.
Dhrystone 2 without register variables 2368680.4 lps (10 secs, 6 samples)
Dhrystone 2 using register variables 2138532.7 lps (10 secs, 6 samples)
Arithmetic Test (type = arithoh) 3047742.0 lps (10 secs, 6 samples)
Arithmetic Test (type = register) 145400.3 lps (10 secs, 6 samples)
Arithmetic Test (type = short) 126624.1 lps (10 secs, 6 samples)
Arithmetic Test (type = int) 143236.6 lps (10 secs, 6 samples)
Arithmetic Test (type = long) 157815.3 lps (10 secs, 6 samples)
Arithmetic Test (type = float) 444529.1 lps (10 secs, 6 samples)
Arithmetic Test (type = double) 407111.3 lps (10 secs, 6 samples)
System Call Overhead Test 247231.5 lps (10 secs, 6 samples)
Pipe Throughput Test 350931.2 lps (10 secs, 6 samples)
Pipe-based Context Switching Test 82263.6 lps (10 secs, 6 samples)
Process Creation Test 934.4 lps (10 secs, 6 samples)
Execl Throughput Test 273.1 lps (9 secs, 6 samples)
File Read (10 seconds) 711424.0 KBps (10 secs, 6 samples)
File Write (10 seconds) 1000.0 KBps (10 secs, 6 samples)
File Copy (10 seconds) 1004.0 KBps …read more
Source: FULL ARTICLE at The UNIX and Linux Forums

Business, Finance, Occupation & Industry

MET Crosses Above Key Moving Average Level

Leave a comment

By DividendChannel.com In trading on Wednesday, shares of MetLife Inc (NYSE: MET) crossed above their 200 day moving average of $33.49, changing hands as high as $35.08 per share. MetLife Inc shares are currently trading up about 6.2% on the day. The chart below shows the one year performance of MET shares, versus its 200 day moving average:
Source: FULL ARTICLE at Forbes Markets